10-K Decoder · All companies

ImmunityBio, Inc.

IBRX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$113M$14.7M+669%
Operating income−$256M−$344M+25.6%
Net income−$351M−$414M+15.0%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026

$Q3 2026Year earlierChange
Revenue$48.8M$32.1M+52.0%
Operating income−$78.0M−$55.6M−40.3%
Net income−$185M−$67.3M−174%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was ImmunityBio's revenue in FY2025?
$113M in FY2025 (Fiscal year ended Dec 31, 2025), +669% vs $14.7M a year earlier, per its 10-K filed Feb 2026.
Was ImmunityBio profitable in FY2025?
No: net income was −$351M and operating income −$256M in FY2025.
What was ImmunityBio's revenue in Q3 2026?
$48.8M (+52.0% vs a year earlier), per its Form 10-Q filed Nov 9, 2026.